Trilaciclib and eribulin for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve outcomes in people with advanced triple-negative breast cancer who have already tried at least two other chemotherapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have triple-negative breast cancer that has spread or cannot be removed by surgery, and you have received at least two prior chemotherapy treatments.
- You have at least one measurable tumor (visible on scans) and good blood, liver, and kidney function.
- You can care for yourself (ECOG score 0 or 1) and are expected to live at least 3 months.
- You have not had a stroke or serious heart event in the last 6 months, and your heart rhythm (QTc) is within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy. It is for people with several types of advanced solid tumors who will receive a specific chemo combination (paclitaxel plus carboplatin) for the first time.
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
This trial tests whether combining the immunotherapy drug cadonilimab with the chemotherapy eribulin works better than eribulin alone for people with recurrent or metastatic triple-negative breast cancer. It aims to see if the combination can shrink tumors or slow the disease.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.